Establishing a Clear & Predictable UK Regulatory Pathway to Accelerate Clinical Phage Access
- Examining how MHRA, NICE and NHS England are shaping a national framework for phage therapy evaluation
- Understanding opportunities created by the Innovative Medicines Fund and adaptive licensing pilots
- Outlining the next steps needed to transition from compassionate-use approvals to standardised national access